financetom
Business
financetom
/
Business
/
Bath & Body Works Delivers Growth Amid Challenges, Beats Q3 Expectations And Lifts 2024 Projections
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bath & Body Works Delivers Growth Amid Challenges, Beats Q3 Expectations And Lifts 2024 Projections
Nov 25, 2024 6:13 AM

Bath & Body Works, Inc. ( BBWI ) shares are trading higher after the company reported better-than-expected third-quarter results and raised its 2024 outlook.

BBWI’s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents.

Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.

The gross margin was 43.5%, down 20 bps YoY, and the operating margin was 13.5% compared to 14.2% YoY.

Related: Bath & Body Works Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

“Innovation across our core products, adjacencies, and collaborations is resonating with both new and existing customers supported by the investments we have made in marketing and technology. We are capitalizing on our agile business model and predominantly U.S.-based supply chain, and we believe we are well-positioned to navigate a volatile retail environment and shorter holiday calendar,” commented Gina Boswell, CEO of Bath & Body Works ( BBWI ).

Net cash used for operating activities year-to-date totaled $69 million, compared to cash provided of $28 million a year ago.

Bath & Body Works ( BBWI ) exited the quarter with cash and equivalents of $191 million. The company’s inventories as of quarter end totaled $1.178 billion, with long-term debt of $3.88 billion.

Bath & Body Works ( BBWI ) had recently declared a regular quarterly dividend of $0.20 per share, payable on December 6, 2024, to shareholders of record at the close of business on November 22, 2024.

Also Read: Bath & Body Works Stock Downgraded Due To This Risk: Details

Q4 Outlook: Bath & Body Works ( BBWI ) projects net sales to decline of 6.5% to a decline of 4.5% year-over-year, reflecting a 500-basis-point headwind from a shifted fiscal calendar. Earnings per share are expected to be between $1.94 and $2.07, versus the $1.98 consensus.

2024 Outlook: The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.

Price Action: BBWI shares are trading higher by 19.2% at $36.61 premarket at the last check Monday.

Image via Unsplash

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved